News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
38,808 Results
Type
Article (2456)
Company Profile (39)
Press Release (36313)
Multimedia
Podcasts (4)
Webinars (2)
Section
Business (14266)
Career Advice (80)
Deals (2099)
Drug Delivery (9)
Drug Development (4167)
Employer Resources (10)
FDA (439)
Job Trends (768)
News (20362)
Policy (1066)
Tag
2024 BioForest Digital (4)
2024 BioMidwest Digital (2)
2024 Biotech Bay Standard (2)
2024 Biotech Beach Digital (1)
2024 Biotech Beach Standard (1)
2024 Lone Star Bio Digital (1)
2024 Pharm Country Digital (1)
2025 Lone Star Bio Digital (1)
Academia (149)
Allergies (6)
Alliances (3510)
ALS (4)
Alzheimer's disease (46)
Antibody-drug conjugate (ADC) (18)
Approvals (441)
Artificial intelligence (13)
Autoimmune disease (3)
Automation (1)
Bankruptcy (12)
Best Places to Work (479)
BIOSECURE Act (2)
Biosimilars (12)
Biotechnology (30)
Bladder cancer (6)
Brain cancer (5)
Breast cancer (20)
Cancer (152)
Cardiovascular disease (5)
Career advice (67)
Career pathing (1)
CAR-T (16)
Cell therapy (50)
Cervical cancer (2)
Clinical research (3244)
Collaboration (97)
Compensation (51)
COVID-19 (182)
CRISPR (8)
C-suite (31)
Cystic fibrosis (2)
Data (123)
Denatured (3)
Depression (3)
Diabetes (10)
Diagnostics (500)
Digital health (1)
Diversity, equity & inclusion (1)
Drug discovery (15)
Drug pricing (7)
Duchenne muscular dystrophy (12)
Earnings (4280)
Editorial (3)
Employer branding (1)
Employer resources (8)
Events (6170)
Executive appointments (100)
FDA (488)
Featured Employer (3)
Funding (81)
Gene editing (15)
Gene therapy (22)
GLP-1 (60)
Government (151)
Guidances (1)
Healthcare (728)
Huntington's disease (3)
IgA nephropathy (4)
Immunology and inflammation (17)
Indications (2)
Infectious disease (187)
Inflammatory bowel disease (11)
Inflation Reduction Act (6)
Influenza (4)
Intellectual property (10)
Interviews (7)
IPO (999)
IRA (7)
Job creations (290)
Job search strategy (65)
Kidney cancer (4)
Labor market (4)
Layoffs (39)
Leadership (1)
Legal (214)
Liver cancer (6)
Lung cancer (15)
Lymphoma (4)
Management (4)
Manufacturing (20)
MASH (4)
Medical device (310)
Medtech (310)
Mergers & acquisitions (1175)
Metabolic disorders (34)
Multiple sclerosis (9)
Neurodegenerative disease (9)
Neuropsychiatric disorders (3)
Neuroscience (95)
NextGen: Class of 2025 (370)
Non-profit (161)
Northern California (386)
Now hiring (4)
Obesity (16)
Opinion (15)
Ovarian cancer (10)
Pain (10)
Pancreatic cancer (3)
Parkinson's disease (4)
Partnered (2)
Patents (23)
Patient recruitment (5)
Peanut (1)
People (5732)
Pharmaceutical (5)
Phase I (1405)
Phase II (1627)
Phase III (853)
Pipeline (85)
Policy (12)
Postmarket research (31)
Preclinical (601)
Press Release (2)
Prostate cancer (4)
Psychedelics (2)
Radiopharmaceuticals (13)
Rare diseases (25)
Real estate (422)
Recruiting (5)
Regulatory (819)
Reports (6)
Research institute (156)
Resumes & cover letters (9)
RNA editing (1)
Schizophrenia (12)
Series A (25)
Series B (5)
Service/supplier (2)
Sickle cell disease (1)
Southern California (373)
Special edition (1)
Spinal muscular atrophy (2)
Sponsored (1)
Startups (490)
Stomach cancer (1)
Supply chain (4)
The Weekly (1)
United States (1838)
Vaccines (29)
Venture capitalists (8)
Weight loss (12)
Women's health (1)
Worklife (1)
Date
Today (15)
Last 7 days (96)
Last 30 days (261)
Last 365 days (2581)
2025 (878)
2024 (2625)
2023 (2870)
2022 (3780)
2021 (4112)
2020 (3546)
2019 (2098)
2018 (1573)
2017 (1810)
2016 (1642)
2015 (1849)
2014 (1387)
2013 (1200)
2012 (1410)
2011 (1347)
2010 (1190)
Location
Africa (43)
Alabama (1)
Arizona (15)
Asia (1896)
Australia (305)
California (887)
Canada (138)
China (41)
Colorado (21)
Connecticut (10)
Delaware (4)
Europe (3893)
Florida (45)
Georgia (6)
Idaho (3)
Illinois (14)
India (1)
Indiana (33)
Japan (8)
Kansas (12)
Maryland (26)
Massachusetts (327)
Michigan (9)
Minnesota (14)
Missouri (3)
Nebraska (1)
Nevada (3)
New Hampshire (2)
New Jersey (72)
New York (51)
North Carolina (92)
Northern California (386)
Ohio (26)
Oklahoma (2)
Oregon (5)
Pennsylvania (54)
Rhode Island (2)
South America (40)
South Carolina (1)
Southern California (373)
Tennessee (2)
Texas (75)
Utah (2)
Virginia (6)
Washington D.C. (1)
Washington State (54)
Wisconsin (6)
38,808 Results for "maxwell biosciences".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Maxwell Biosciences Secures Anti-Diarrheal US Military Agreement
Maxwell’s 7th signed US military agreement is for in vitro testing of Maxwell’s Claromers for the treatment of diarrheal pathogens
April 23, 2025
·
3 min read
Press Releases
Maxwell Biosciences Secures US Military Research Agreement to Combat Dengue Fever
U.S. Naval Infectious Diseases Diagnostic Laboratory to study dengue fever activity of Claromer antiviral compounds, combatting a rapidly growing mosquito-borne viral infection and a national priority biodefense threat
February 26, 2025
·
4 min read
Press Releases
Maxwell Biosciences Secures US Military Agreement to Research Scientific Aspects of Claromer Technology
U.S. Army Institute of Surgical Research to conduct key studies intended to further our knowledge of the effects of Claromer technology
March 5, 2025
·
2 min read
Press Releases
Maxwell Biosciences Announces Appointment of José Antonio Alas to Its Board of Directors
Appointment of José Antonio Alas brings more than 30 years of biotech expertise, including global business development, international partnerships, patient access to innovative medications and product launches as the company advances its Claromer drug discovery platform
January 22, 2025
·
2 min read
Business
Maxwell Biosciences CEO J. Scotch McClure Named Top 25 Executive in Biotechnology
Austin, Texas--(Newsfile Corp. - May 15, 2024) - Maxwell Biosciences, Inc, a pre-clinical drug platform company focused on developing biomimetic therapeutics that improve upon natural immune system peptides...
May 15, 2024
·
2 min read
Drug Development
Maxwell Biosciences Enters Second CRADA with USAMRIID to Test Claromer Compounds as Potential Therapeutics for Viral and Bacterial Pathogens
Austin, Texas--(Newsfile Corp. - May 8, 2024) - Maxwell Biosciences, a preclinical drug platform company focused on developing biomimetic therapeutics that improve upon natural immune system peptides based on its patented Claromer® technology platform...
May 8, 2024
·
3 min read
Press Releases
Maxwell Biosciences Selected to Receive a Nearly $3M Award from Medical Technology Enterprise Consortium (MTEC)
October 24, 2024
·
3 min read
Business
Maxwell Biosciences Appoints Major General (Ret.) Barb Holcomb, RN, BSN, MSN to Its Board of Directors
Maxwell Biosciences (“Maxwell”), a preclinical drug platform company developing a synthetic immune system that may serve as a key biodefense asset, today announced the appointment of Major General (Retired) Barb Holcomb, RN, BSN, MSN to its Board of Directors.
October 18, 2023
·
4 min read
Maxwell Biosciences Announces Promising Activity of Claromer Compound Against Ebola Virus in a Research Study
Maxwell Biosciences, Inc., (MXB) a pre-clinical drug platform company focused on developing biomimetic therapeutics that improve upon natural immune system peptides based on its patented Claromer® technology platform
November 2, 2023
·
3 min read
Lone Star Bio
Maxwell Biosciences Announces Publication of Mechanism of Action Study: Claromer Compounds Target Pathogens by Disrupting Their Membranes
Maxwell Biosciences, a pioneering preclinical drug platform company, today announced publication of a revolutionary mechanism of action study for their Claromer® compounds in the journal ACS Infectious Diseases.
August 2, 2023
·
4 min read
1 of 3,881
Next
